Toronto, Canada, May 16, 2017 – BresoDx®, developed by BresoTec, has been selected by the Ministry of Health and Long-Term Care (MOHLTC) for use in a home-based sleep apnea demonstration project with sleep clinics across Ontario. For the first time in the province,patients and sleep physicians will have the option to diagnose sleep apnea in the home.
Invented at the Toronto Rehabilitation Institute by Dr. Hisham Alshaer, BresoDx® is the world’s first cordless, single-user, home sleep test used to diagnose sleep apnea. BresoDx® aims ...
Applications for next MSc PoP granting round being accepted until February 25, 2016
TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children.
Applications for the next MSc PoP granting round are open until March 4, 2016. To ...
BresoTec, formerly known as ApneaDx, also among top five finalists
TORONTO, August 11, 2015 – Legworks' next-generation prosthetic knee took first place in Ontario Centres of Excellence’s (OCE’s) Parapan Am Games-affiliated Accessibility Tech Pitch competition. The company immediately said it would use the $20,000 award to fit 200 amputees in developing countries with its device.
Legworks was selected from 18 participants in a two-day elimination pitch competition – one of the features of the Government of Ontario’s Accessibility Innovation Showcase held at MaRS ...
There's been lots of activity in MI's portfolio this week (and it's only Wednesday). Read down for what you need to know about Whirlscape, Crowdmark, OtoSim, and ApneaDx.
Whirlscape launches Google Glass demo video
Whirlscape's Minuum keyboard nabbed a four-star review from CNET's editors only days before announcing their technology is now available for Google Glass. Watch the UTEST graduate's newest demo video.
Reaction coverage: BNN, the Telegraph (U.K.), WPRO (radio), CNET, Mashable, TechCrunch, Mobile Syrup and Android Central, among various other tech blogs.
2013 was an exceptional year for MaRS Innovation. Here are the top 10 news stories from our commercialization portfolio.
1. MaRS Innovation secures a $15 million CECR funding extension
In January, MaRS Innovation was one of four Centres of Excellence for Commercialization and Research to be successfully extended by the Networks of Centres of Excellence of Canada.
This achievement reflects and recognizes the quality of the startups and licensable technologies within the MaRS Innovation portfolio, as well as the rigour of its business model and the achievements of its ...
President and CEO Dr. Raphael Hofstein speaks on healthcare innovation in Toronto
In an October 30 article, Yonge Street Media's Andrew Seale spoke with MI’s president and CEO Raphael Hofstein on the booming healthcare innovation coming from Toronto since 2005.
Seale's article is the first of a two-part series on technological innovation.
In the article, Hofstein credits the city’s intellectual infrastructure and access to healthcare resources for allowing innovation to flourish.
Three of MI’s start-up companies are also mentioned in the article.
Here’s an excerpt (links and ...
MaRS Innovation (MI) seeks applicants for the Medical Sciences Proof-of-Principle (MSc PoP) program, which supports early-stage medical science technologies and allows their founding teams to conduct crucial proof-of-principle work.
Through the two-year MSc POP program, MI will distribute funding awards to qualified applicants within its membership on behalf of the Ministry of Research and Innovation (MRI). Funds are available in $25,000 or $75,000 grants.
“At MaRS Innovation, the PoP program functions as a kind of internal Dragons' Den,” says Dr. Raphael Hofstein, president ...
Dr. Raphael (Rafi) Hofstein is president and CEO of MaRS Innovation (MI) – the commercialization agent for an exceptional research discovery pipeline stemming from 16 leading Ontario academic institutions. As a single entry point to annual member research and development activity of $1B, MI provides a gateway for investors and licensees who wish to access Ontario’s technology assets.
During the 2012 BIO convention in Boston, Dr. Hofstein blogged about how CQDM of Montreal and MaRS Innovation of Toronto had teamed up to ...
MI start-up ApneaDx Inc. among program's first round of participants
The first three companies selected to participate in the MaRS EXCITE program aim to improve outcomes for breast cancer, sleep apnea and drug-resistant hypertension.
The Excellence in Clinical Innovation and Technology Evaluation (EXCITE) initiative helps companies accelerate the adoption and reimbursement of innovative health technologies through a single, harmonized, pre-market, evidence-based process.
EXCITE has selected ApneaDx Inc., Medtronic of Canada Ltd. and Rna Diagnostics Inc. as the program’s initial participants. (more…)
Happy New Year. Here's a snapshot of some spin-off stories you may have missed over the holiday break:
Flybits and Flybits Lite, the startup company's context-aware mobile technology that anyone can use, was mentioned in a Smithsonian.com article as one of six technologies changing the way the way humans live.
ApneaDx was featured in a company profile post on the MaRS Blog: "ApneaDx: First we take Ontario, then we take the world."
ScarX Therapeutics launched its website.
OtoSim Inc. co-founder Dr. Vito ...